Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.56), $0.16 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $2.14 million versus the consensus estimate of $1.69 million.

Financial Guidance

Cara expects that our current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently anticipated operating plan into 2026. Our current operating plan assumes certain costs related to our planned pivotal trials in NP.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.